About zPREDICTA
zPREDICTA is a Healthcare company based in San Jose (United States) founded in 2014, and was acquired by Predictive Oncology in December 2021. Tumor-specific in vitro 3D models are supplied for drug development. zPREDICTA has raised $220 thousand across 2 funding rounds from investors including Predictive Oncology, Propel(x) and Y Combinator. The company has 3 employees. zPREDICTA offers products and services including 3D Cell Culture Models and Tumor-Specific In Vitro Models. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Animal Models. Its legal entity is ZPREDICTA INC. Its competitors include Yecuris, Sagres Discovery and Genomab Biotech; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2014 and headquartered in San Jose, United States, tumor-specific in vitro 3D models are developed for applications in cancer drug screening. The proprietary PD-3D platform is utilized to replicate human in vivo conditions in assays. Reconstructed bone models under the rBone product line are offered for testing potential therapeutics in oncology. Operations focus on biotechnology services supporting pharmaceutical research and development.
- Headquarters San Jose, United States
- Employees 3
- Stage Acquired
- SectorsHealthcare
- Website zpredicta.com
- Social LinkedIn X Facebook Instagram
- Acquired by Predictive Oncology (Dec 2021)
- Legal Name Zpredicta Inc
- Total Equity Funding$220K (USD)
in 2 rounds
- Latest Funding Round$100K (USD), Seed
Jun 2016
- InvestorsPredictive Oncology
& 2 more
- Employee Count3
- Acquired byPredictive Oncology
(Dec 2021)
Products & Services of zPREDICTA
zPREDICTA offers a comprehensive portfolio of products and services, including 3D Cell Culture Models and Tumor-Specific In Vitro Models.
Provides 3D models for evaluating anticancer agents in human-like tissue.
Enables testing of drug responses in organ-specific disease environments.
Funding Insights of zPREDICTA
zPREDICTA has successfully raised a total of $220K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $100 thousand completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $220,000
- Total Rounds 2
- Last Round Seed — $100,000
- First Round $120,000
(Aug 2015)
- Investors Count 2
All 2 funding rounds of zPREDICTA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $100,000 | Seed | – | – | |
| Aug 2015 | $120,000 | Seed | – | – |
3 investors in total: 3 institutional.
Investors in zPREDICTA
zPREDICTA has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Predictive Oncology, Propel(x) and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Deep technology startups are funded via equity crowdfunding platform. | 2014 | propelx.com | San Francisco, United States | |
AI-based platform for cancer diagnostics and precision medicine is utilized. | 2002 | predictive-oncology.com | Eagan, United States |
Investor details for zPREDICTA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of zPREDICTA
4 dated milestones of zPREDICTA across 7 years, from founding to its latest funding, stage changes and deals.
- Founded zPREDICTA is founded.
- Funding First funding round of $120K.
- Funding Latest funding round, Seed, of $100K.
- Exit Acquired by Predictive Oncology.
Competitors of zPREDICTA
zPREDICTA has 3 listed competitors in our database, 2 of them funded. They include Yecuris, Sagres Discovery and Genomab Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| yecuris.com | 2007 | Tualatin, United States | $1.25M | 26 | Humanized liver rodent models are developed for biology research. | |
| sagresdiscovery.com | 2000 | Davis, United States | $20M | Creates innovative mouse models to analyze genes causing cancer diseases. | ||
| genomab.com | 2015 | New York, United States | Developer of humanized mouse models for preclinical studies and precision medicine |
Detailed competitors of zPREDICTA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as zPREDICTA (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zpredicta
Complete news archive for zPREDICTA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about zPREDICTA
zPREDICTA was founded in 2014 and raised its 1st funding round 1 year after it was founded.
zPREDICTA is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
zPREDICTA is a funded company, having raised a total of $220K across 2 funding rounds to date. The company's 1st funding round was a Seed of $120K, raised on Aug 2015.
zPREDICTA has 3 employees.
Founded in 2014 and headquartered in San Jose, United States, tumor-specific in vitro 3D models are developed for applications in cancer drug screening. The proprietary PD-3D platform is utilized to replicate human in vivo conditions in assays. Reconstructed bone models under the rBone product line are offered for testing potential therapeutics in oncology. Operations focus on biotechnology services supporting pharmaceutical research and development.
zPREDICTA's top competitors include Yecuris, Genomab Biotech and Sagres Discovery.
zPREDICTA offers 3D Cell Culture Models and Tumor-Specific In Vitro Models.
zPREDICTA has 3 investors. Key investors include Predictive Oncology, Propel(x), and Y Combinator.
zPREDICTA operates through Zpredicta Inc.
Yes. zPREDICTA was acquired by Predictive Oncology in December 2021.